OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN324 achieves faster, greater, and more durable reductions in wAMD pigment epithelial detachment (PED) thickness versus faricimab Ollin and Innovent Biologics advancing OLN324 into global Phase 3 studies in DME and wAMD in 2026 SAN FRANCISCO and SUZHOU, China

Clinical Trial will use blood tests to detect cellular evidence of cancer—and a therapeutic vaccine to try to stop it HOUSTON and NEW YORK, March 30, 2026 /PRNewswire/ -- The Cancer Vaccine Coalition (CVC), through its strategic partnership with the V Foundation for Cancer Research, is announcing a $1 million grant toward a Phase II study at The University of Texas MD Anderson Cancer Center. The INTERCEPT-HER2 clinical trial is designed to potentially catch cancer at its earliest molecular signa

VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP® XL venous vascular closure system to include procedures using 10-14F inner diameter (ID) and up to 17F

First histotripsy system in Missouri; among first 100 in the U.S. ST. LOUIS, March 30, 2026 /PRNewswire/ -- Tumors destroyed by bubble clouds may sound like science fiction, but surgical oncologists at Mercy Hospital St. Louis will soon make it a reality. Mercy will be the first in Missouri to treat liver tumors with the Edison® Histotripsy System, a completely non-invasive technology that liquefies tumors without surgery, chemotherapy or radiation. The first patient procedure is slated for late

AUSTIN, Texas, March 30, 2026 /PRNewswire/ -- The Texas Healthcare & Bioscience Institute (THBI), the statewide public policy voice of the healthcare and bioscience industry, today released a comprehensive report outlining a strategic vision for strengthening Texas' life sciences and biotechnology ecosystem. "Texas Life Sciences: Driving Innovation, Patient Care & Economic Growth" highlights the state's rapid growth in bioscience employment, research investment, and innovation while offering act

POMONA, Calif., March 30, 2026 /PRNewswire/ -- Western University of Health Sciences' College of Osteopathic Medicine of the Pacific (COMP) achieved 100% residency placement for the third consecutive year. COMP celebrated Match Day on March 20, 2026, in Ontario, California, joining medical students across the country in learning where they would begin their clinical training. COMP Class of 2026 students shared this special moment with family, friends and classmates as they opened envelopes conta

New multicenter analysis highlights IntelliSep's clinical usability and impact on frontline physician decision-making, strengthening existing real-world evidence SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- A new peer-reviewed study published in JACEP Open found that providing emergency department (ED) physicians with IntelliSep® sepsis test results was associated with improved diagnostic accuracy and confidence when evaluating patients for sepsis. In the multicenter, vignette-based study, diag

Bill Unrigs Medical Arbitration Process by Reducing Financial Incentives that Skew the Process Away From Malpractice Victims/Survivors and Toward Health Plan Providers SACRAMENTO, Calif., March 30, 2026 /PRNewswire/ -- The Patient Equity Coalition announced that Assistant Majority Leader Robert Garcia (D-Rancho Cucamonga) will be naming AB 1770 "Lindalee's Law" in honor of Lindalee Iverson, a Southern California woman whose misdiagnosed breast cancer and subsequent experiences in the medical arb

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26), reinforcing the potential of RNAi to deliver fundamentally differentiated, effective, and durable impact for patients living with cardiovascular disease (CVD). New data continue to support the use

AUSTIN, Texas, March 30, 2026 /PRNewswire/ -- Family Care Center opened a new outpatient behavioral health clinic in South Austin, its sixth location in the Austin region. The clinic addresses the growing demand for mental health care in Texas and brings multiple services together under one roof. Patients at the South Austin clinic can now access therapy, psychiatry, medication management, and advanced treatments such as transcranial magnetic stimulation (TMS) in a coordinated, integrated settin